Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New appointment at Merck & Co

This article was originally published in Scrip

Executive Summary

Merck & Co has named Dr Michael Mendelsohn senior vice-president of Merck Research Laboratories and franchise head, atherosclerosis and cardiovascular research. He joins the company after 17 years at Tufts Medical Center in Boston. He was the founder and for twelve years the executive director of the Center's Molecular Cardiology Research Institute, and for the past two years served as the first chief scientific officer at Tufts. Dr Mendelsohn will be based at Merck's site in Rahway, New Jersey, and will report to the company's senior vice-president, global scientific strategy, Dr Luciano Rossetti.

You may also be interested in...



‘Ready For Day 1’ – UK MHRA’s Statement Of Intent For Post-Brexit Medtech Regulatory System

The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.

African Platform Eyes $750m Investment

Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.

Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease

The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.

Topics

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel